DTCs in breast cancer: clinical research and practice.

[1]  K. Pantel,et al.  Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ , 2011, International journal of cancer.

[2]  T. Fehm,et al.  Persistence of Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients Predicts Increased Risk for Relapse—A European Pooled Analysis , 2011, Clinical Cancer Research.

[3]  H. Kuerer,et al.  Disseminated Tumor Cells in Biologic Subtypes of Stage I–III Breast Cancer Patients , 2010, Annals of Surgical Oncology.

[4]  M. Ellis,et al.  Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. , 2010, The Lancet. Oncology.

[5]  H. Sommer,et al.  Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. , 2010, Anticancer research.

[6]  T. Fehm,et al.  Clinical Relevance of Disseminated Tumor Cells in the Bone Marrow and Circulating Tumor Cells in the Blood of Breast Cancer Patients , 2009, Breast Care.

[7]  T. Fehm,et al.  Comparison of HER2 status between primary tumor and disseminated tumor cells in␣primary breast cancer patients , 2006, Breast Cancer Research and Treatment.

[8]  T. Fehm,et al.  A pooled analysis of bone marrow micrometastasis in breast cancer. , 2005, The New England journal of medicine.

[9]  Thomas Rau,et al.  Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity , 2005, Clinical Cancer Research.

[10]  Tanja Fehm,et al.  HER-2 gene amplification can be acquired as breast cancer progresses. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Jason L. Townson,et al.  Ineffectiveness of Doxorubicin Treatment on Solitary Dormant Mammary Carcinoma Cells or Late-developing Metastases , 2003, Breast Cancer Research and Treatment.

[12]  S. Braun,et al.  Biological Characteristics of Micrometastatic Cancer Cells in Bone Marrow , 1999, Cancer and Metastasis Reviews.

[13]  Joe W Gray,et al.  Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. , 2003, Cancer cell.

[14]  J. Köllermann,et al.  Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Braun,et al.  The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence , 2001, Cancer.

[16]  S. Braun,et al.  ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. , 2001, Cancer research.

[17]  T. Dimpfl,et al.  Prognostic significance of an increased number of micrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma , 2000, Cancer.

[18]  T. Dimpfl,et al.  Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.

[19]  H Sommer,et al.  Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  N. Davidson,et al.  Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. , 1993, Blood.

[21]  J. Izbicki,et al.  Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. , 1993, Journal of the National Cancer Institute.